Swing Trading Penny Stocks
Swing trading penny stocks refers to the practice of trying to profit from market swings of a minimum of one day and as long as several weeks. In contrast to swing traders, day traders usually are in and out of the market in one day and trend traders often hold positions for several months. So, in terms of length of holding a trade, swing traders are in-between day traders and trend traders.
Each type of trading has its advantages and disadvantages. The appeal of swing trading is that it provides plenty of opportunities to trade; the dollar risk per trade is lower than with trend trading because of closer stops; it provides greater profit opportunity per trade than day trading; quick rewards provide emotional satisfaction. The downside of swing trading is that you must work hard all the time to manage trades; you are quite likely to miss major moves where huge profits can be made; frequent trading results in higher commission costs.
A good argument can be made that beginning traders would be well-served to start with swing trading as it allows enough trading action to gain experience; losses can be kept to acceptable levels with proper stop loss techniques, and it provides a good perspective to learn about both the short-term and long-term movements of markets.
Make sure to create a watchlist. These are simply stocks that have a fundamental catalyst and a shot at being a good trade. Some swing traders like to keep a dry-erase board next to their trading stations with a categorized list of opportunities, entry prices, target prices, and stop-loss prices.
Best Penny Stocks to Trade is a group whose objective is to help traders find the best swing trades for success.
Our alerts/signals come from an algorithmic system that we created for penny stock/ OTC swinging.
Before we release our system to the public, we’re going to spend the next 6 months posting alerts. You will be able to look back at these alerts to see how successful they are.
Penny Stock Swing Trade Alert for 3.17.2020 —> HTBX
Heat Biologics, Inc. (“Heat”)(HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutic vaccines including one for coronavirus COVID-19, today announced that it has accepted an invitation to join the Alliance for Biosecurity, a DC-based coalition of pharmaceutical and biotechnology companies that works to ensure medical countermeasures are available to protect public health and improve the prevention and treatment of severe infectious diseases, including coronavirus COVID-19.
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate a patient’s immune system against cancer through T-cell activation.
The company’s T-cell activation platform includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, dual-acting immunotherapy, which delivers antigen-driven T-cell activation and specific co-stimulation in a single product.
It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. Its preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling.
The company has a strategic collaboration with the University of Miami Miller School of Medicine. Heat Biologics, Inc. was founded in 2008 and is headquartered in Durham, North Carolina.